Evidence map›Paper›PMID 36768769›Full record

ArticleInternational journal of molecular sciences2023

Foggia Prostate Cancer Risk Calculator 2.0: A Novel Risk Calculator including MRI and Bladder Outlet Obstruction Parameters to Reduce Unnecessary Biopsies.

Ugo Giovanni Falagario, Gian Maria Busetto, Marco Recchia, Edoardo Tocci, Oscar Selvaggio, Antonella Ninivaggi, Paola Milillo, Luca Macarini, Francesca Sanguedolce, Vito Mancini and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ugo Giovanni FalagarioDepartment of Urology and Organ Transplantation, University of Foggia, 71122 Foggia, Italy.
Gian Maria BusettoDepartment of Urology and Organ Transplantation, University of Foggia, 71122 Foggia, Italy.ORCID 0000-0002-7291-0316
Marco RecchiaDepartment of Urology and Organ Transplantation, University of Foggia, 71122 Foggia, Italy.
Edoardo TocciDepartment of Urology and Organ Transplantation, University of Foggia, 71122 Foggia, Italy.
Oscar SelvaggioDepartment of Urology and Organ Transplantation, University of Foggia, 71122 Foggia, Italy.
Antonella NinivaggiDepartment of Urology and Organ Transplantation, University of Foggia, 71122 Foggia, Italy.
Paola MililloDepartment of Radiology, University of Foggia, 71122 Foggia, Italy.
Luca MacariniDepartment of Radiology, University of Foggia, 71122 Foggia, Italy.
Francesca SanguedolceDepartment of Pathology, University of Foggia, 71122 Foggia, Italy.
Vito ManciniDepartment of Urology and Organ Transplantation, University of Foggia, 71122 Foggia, Italy.
Pasquale AnneseDepartment of Urology and Organ Transplantation, University of Foggia, 71122 Foggia, Italy.
Carlo BettocchiDepartment of Urology and Organ Transplantation, University of Foggia, 71122 Foggia, Italy.
Giuseppe CarrieriDepartment of Urology and Organ Transplantation, University of Foggia, 71122 Foggia, Italy.
Luigi CormioDepartment of Urology and Organ Transplantation, University of Foggia, 71122 Foggia, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Risk calculator (RC) combining PSA with other clinical information can help to better select patients at risk of prostate cancer (PCa) for prostate biopsy. The present study aimed to develop a new Pca RC, including MRI and bladder outlet obstruction parameters (BOOP). The ability of these parameters in predicting PCa and clinically significant PCa (csPCa: ISUP GG ≥ 2) was assessed by binary logistic regression. A total of 728 patients were included from two institutions. Of these, 395 (54.3%) had negative biopsies and 161 (22.11%) and 172 (23.6%) had a diagnosis of ISUP GG1 PCa and csPCa. The two RC ultimately included age, PSA, DRE, prostate volume (pVol), post-voided residual urinary volume (PVR), and PIRADS score. Regarding BOOP, higher prostate volumes (csPCa: OR 0.98, CI 0.97,0.99) and PVR ≥ 50 mL (csPCa: OR 0.27, CI 0.15, 0.47) were protective factors for the diagnosis of any PCa and csPCa. AUCs after internal validation were 0.78 (0.75, 0.82) and 0.82 (0.79, 0.86), respectively. Finally, decision curves analysis demonstrated higher benefit compared to the first-generation calculator and MRI alone. These novel RC based on MRI and BOOP may help to better select patient for prostate biopsy after prostate MRI.

Indexed as

Prostatic NeoplasmsUrinary Bladder Neck ObstructionBiopsyHumansMagnetic Resonance ImagingMaleProstate-Specific AntigenProstate-Specific Antigenbladder outlet obstructionPIRADSprostate cancerrisk calculator

Identifiers

PMID36768769
PMCPMC9917125

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.